Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions

Neuroendocrine Tumors

Interventions

DRUG

AdVince

Virus solution for infusion in intrahepatic artery

Trial Locations (1)

Endocrine Oncology Clinic, Uppsala University Hospital, Uppsala

All Listed Sponsors

lead

Uppsala University

OTHER

NCT02749331 - Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy | Biotech Hunter | Biotech Hunter